Phase 2 Study of Panitumumab Plus Irinotecan Followed by Panitumumab Plus AMG 479 in Subjects With Metastatic Colorectal Carcinoma Expressing Wild Type KRAS and Refractory to Oxaliplatin-or Irinotecan- and Oxaliplatin-Containing Regimens to Evaluate Mechanisms of Acquired Resistance to Panitumumab.

Trial Profile

Phase 2 Study of Panitumumab Plus Irinotecan Followed by Panitumumab Plus AMG 479 in Subjects With Metastatic Colorectal Carcinoma Expressing Wild Type KRAS and Refractory to Oxaliplatin-or Irinotecan- and Oxaliplatin-Containing Regimens to Evaluate Mechanisms of Acquired Resistance to Panitumumab.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Ganitumab (Primary) ; Panitumumab (Primary) ; Irinotecan
  • Indications Colorectal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jan 2013 Planned end date changed from 1 Oct 2014 to 1 Apr 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top